PhenomeX

PhenomeX EBIT

Delisted

The EBIT of PhenomeX (CELL) as of Oct 24, 2026 is -94.54 M USD. In the previous year, EBIT was -70.78 M USD — a change of 33.56% (lower).

EBIT

-94.54 MUSD

YoY

33.56%

Last updated:

In 2022, PhenomeX's EBIT was -94.54 M USD, a 33.56% increase from the -70.78 M USD EBIT recorded in the previous year.

The PhenomeX EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2019
-17.72 M USD
Jan 1, 2020
-40.31 M USD
Jan 1, 2021
-70.78 M USD
Jan 1, 2022
-94.54 M USD
Jan 1, 2023 (e)
-91.21 M USD
Jan 1, 2024 (e)
-53.08 M USD
Jan 1, 2025 (e)
-44.17 M USD
Jan 1, 2026 (e)
0.00 USD
The PhenomeX EBIT history
YEAREBITYoY
est0.00USD-100.00%
est-44.17 MUSD-16.79%
est-53.08 MUSD-41.81%
est-91.21 MUSD-3.52%
-94.54 MUSD+33.56%
-70.78 MUSD+75.59%
-40.31 MUSD+127.53%
-17.72 MUSD-16.27%
-21.16 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PhenomeX Revenue

PhenomeX Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
56.69 M USD
-17.72 M USD
-18.30 M USD
Jan 1, 2020
64.30 M USD
-40.31 M USD
-41.58 M USD
Jan 1, 2021
85.39 M USD
-70.78 M USD
-71.72 M USD
Jan 1, 2022
78.60 M USD
-94.54 M USD
-98.04 M USD
Jan 1, 2023 (e)
76.01 M USD
-91.21 M USD
-81.96 M USD
Jan 1, 2024 (e)
104.02 M USD
-53.08 M USD
-45.45 M USD
Jan 1, 2025 (e)
135.93 M USD
-44.17 M USD
-19.53 M USD
Jan 1, 2026 (e)
182.58 M USD
0.00 USD
-18.97 M USD

PhenomeX Margins

PhenomeX stock margins

The PhenomeX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PhenomeX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PhenomeX.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
88.18 %
-31.25 %
-32.28 %
Jan 1, 2020
69.29 %
-62.69 %
-64.67 %
Jan 1, 2021
66.23 %
-82.90 %
-84.00 %
Jan 1, 2022
68.43 %
-120.29 %
-124.74 %
Jan 1, 2023 (e)
68.43 %
-120.00 %
-107.82 %
Jan 1, 2024 (e)
68.43 %
-51.03 %
-43.70 %
Jan 1, 2025 (e)
68.43 %
-32.49 %
-14.37 %
Jan 1, 2026 (e)
68.43 %
0.00 %
-10.39 %

PhenomeX Stock analysis

What does PhenomeX do? The company Berkeley Lights Inc. (BLI) is a biotech startup that was founded in 2011 by Eric Hobbs and Igor Khandros in California. They both had experience in the semiconductor electronics field and decided to utilize their skills to develop a new technology that allows researchers to quickly and efficiently investigate cell-specific processes. The concept behind BLI is based on a novel technology called the "Beacon system." Cells are held on thousands of tiny microchips and can be selectively manipulated using beams of light. The Beacon system enables researchers to isolate, analyze, and select cells rapidly and efficiently, significantly speeding up and simplifying the research process. BLI's business model can be described as B2B, as the company sells its technology and services to other companies in the biotech industry. BLI has two different divisions in which it utilizes its technology and expertise: the "OptoSelect" program and the "Beacon Discovery" program. BLI's OptoSelect program offers customers the ability to select precise and specific cell lines from a large array of cultures. BLI utilizes its Beacon technology to quickly and efficiently isolate and select cells, saving valuable time and resources for researchers. These cell lines can then be used in the development of drugs and therapies, increasing the chances of successful market introduction. BLI's Beacon Discovery program is focused on accelerating the discovery process of new drugs and therapies. BLI works closely with its customers to expedite the drug development process. By using the Beacon technology, it is possible to identify and test potential drug candidates more quickly, significantly reducing the development time. BLI also offers a range of products based on the Beacon technology. These include devices such as the Lightning™ Digital Array, a system for multi-omics analysis of gene expression, immune response, and cell cycle; the Beacon® Controller, a system for controlling the Beacon® microchip platform; and the Beacon® Pak for consumables. Since its founding, BLI has conducted multiple funding rounds and raised over $180 million for the development of its technology and services. The company has established strong partnerships with leading companies in the biotech industry and collaborates closely with researchers and universities to advance its technology. Overall, BLI has established itself as a leading provider of biotech technologies. Through the use of its Beacon technology, the company has accelerated and simplified the process of cell analysis and selection, speeding up the development of new drugs and therapies and increasing the chances of successful market introduction. With its state-of-the-art products and services, BLI is well-positioned to continue playing a significant role in the biotech industry in the future. PhenomeX is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing PhenomeX's EBIT

PhenomeX's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of PhenomeX's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

PhenomeX's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in PhenomeX’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about PhenomeX stock

EBIT of PhenomeX is -94.54 M USD in 2022.

EBIT of PhenomeX changed from -70.78 M USD to -94.54 M USD, representing a 33.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT PhenomeX since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's PhenomeX historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PhenomeX

All Key Metrics — PhenomeX